Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + cisplatin + docetaxel + gemcitabine + vinorelbine
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of bevacizumab (a recombinant humanized monoclonal IgG1 antibody that inhibits VEGF), cisplatin (a platinum-based chemotherapy), docetaxel (a taxane), gemcitabine (a pyrimidine antimetabolite), and vinorelbine (a semi-synthetic vinca alkaloid). This combination has been studied as a sequential therapy approach for non-squamous non-small cell lung cancer (NSCLC), where vinorelbine, cisplatin, and bevacizumab (VCB) are administered first, followed by docetaxel, gemcitabine, and bevacizumab (DGB).
02
Targets
VEGFA (Vascular endothelial growth factor A)RNR (Ribonucleotide reductase)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on bevacizumab + cisplatin + docetaxel + gemcitabine + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + cisplatin + docetaxel + gemcitabine + vinorelbine.